1 Ocak 2022 Dergi makalesi Açık Erişim

Arisoy, Mustafa; Saydam, Mehtap; Dolaksiz, Yasemin Ekin; Talay, Cagri; Saglam, Onursal; Demiray, Gokce; Kurtoglu, Emel Dogan

MARC21 XML

<?xml version='1.0' encoding='UTF-8'?>
<record xmlns="http://www.loc.gov/MARC21/slim">
  <leader>00000nam##2200000uu#4500</leader>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="p">user-tubitak-destekli-proje-yayinlari</subfield>
    <subfield code="o">oai:aperta.ulakbim.gov.tr:254613</subfield>
  </datafield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">The aim of this study is to investigate pharmacokinetic parameters of test and reference film tablet formula-tions of a highly variable drug, pinaverium bromide, under fasting conditions and to assess their bioequiva-lence in accordance with the FDA and EMA criteria. A randomised open-label, single oral dose, three -sequence, three-period, semi-replicated, cross-over trial was conducted with 36 healthy subjects. The intra-subject variability of reference products for Cmax and AUC0-tlast was found to be more than 50%. While bio-equivalence was proven according to the FDA reference scaled average bioequivalence approach with only 36 subjects, more than 200 subjects are required to demonstrate bioequivalence in accordance with the EMA bioequivalence guideline. It is believed that the EMA bioequivalence criteria are too stringent for highly vari-able drugs whose intrasubject variability are more than 30% for both Cmax and AUC0-tlast and that in conse-quence the EMA ought to revise their bioequivalence guidelines for such drugs in the future. (c) 2022 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">publication</subfield>
    <subfield code="b">article</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="a">Creative Commons Attribution</subfield>
    <subfield code="u">http://www.opendefinition.org/licenses/cc-by</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Arisoy, Mustafa</subfield>
    <subfield code="u">Drogsan Pharmaceut, 1370 St, 7, TR-06520 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="z">md5:7e1ae9e35114a428a4d70880ea1dd4fd</subfield>
    <subfield code="s">274</subfield>
    <subfield code="u">https://aperta.ulakbim.gov.trrecord/254613/files/bib-e0820beb-2a56-4bc4-a319-1098b1051eed.txt</subfield>
  </datafield>
  <controlfield tag="005">20230728212358.0</controlfield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2022-01-01</subfield>
  </datafield>
  <datafield tag="024" ind1=" " ind2=" ">
    <subfield code="a">10.1016/j.xphs.2022.08.010</subfield>
    <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="542" ind1=" " ind2=" ">
    <subfield code="l">open</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">A Study to Compare Bioequivalence Approach Between FDA and EMA in a Highly Variable Drug: Pinaverium Bromide Film Tablets</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="4">
    <subfield code="v">111</subfield>
    <subfield code="p">JOURNAL OF PHARMACEUTICAL SCIENCES</subfield>
    <subfield code="c">3149-3154</subfield>
    <subfield code="n">11</subfield>
  </datafield>
  <datafield tag="650" ind1="1" ind2="7">
    <subfield code="a">cc-by</subfield>
    <subfield code="2">opendefinition.org</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Saydam, Mehtap</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Dolaksiz, Yasemin Ekin</subfield>
    <subfield code="u">Drogsan Pharmaceut, 1370 St, 7, TR-06520 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Talay, Cagri</subfield>
    <subfield code="u">Drogsan Pharmaceut, 1370 St, 7, TR-06520 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Saglam, Onursal</subfield>
    <subfield code="u">Novagenix Bioanalyt Drug R&amp;D Ctr, Ozal Ave 664, TR-06970 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Demiray, Gokce</subfield>
    <subfield code="u">Novagenix Bioanalyt Drug R&amp;D Ctr, Ozal Ave 664, TR-06970 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Kurtoglu, Emel Dogan</subfield>
    <subfield code="u">Novagenix Bioanalyt Drug R&amp;D Ctr, Ozal Ave 664, TR-06970 Ankara, Turkey</subfield>
  </datafield>
  <controlfield tag="001">254613</controlfield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-tubitak-destekli-proje-yayinlari</subfield>
  </datafield>
</record>